Hot Investor Mandate: Global VC Invests in Therapeutics and Medical Technologies With Strong Interest in Oncology, Immunology, and Rare Diseases

1 Dec

A global venture capital and commercial development firm based in the USA has raised five life science-focused venture funds its flagship Venture Capital business unit and is currently investing out of its fifth fund. In addition, the firm recently closed on a new fund that is investing in companies domiciled in Singapore, Hong Kong and China. The firm generally looks to support companies with lead assets that can reach high value inflection points in 3-4 years and will consider opportunities in US, Canada, Europe, Singapore, Hong Kong and China.

The firm is currently seeking companies developing therapeutics or medical technologies to treat true unmet medical needs. The firm is therapeutic area agnostic, although the firm has historically been most active in immunology, oncology, and rare diseases. The firm typically prefers to invest in Series A/B rounds with a preference for lead assets between 18 months pre-IND and Phase 2a. Within devices, the firm generally prefers to invest in later stage opportunities, particularly those devices that have received market approval with early revenue.

The firm does not have any specific requirements for a firm’s management team. The firm is an active investor and seeks a director or observer position on a company’s board.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: